CN103145798B - Polypeptide of specific binding rare earth nanoparticle and screening method thereof - Google Patents
Polypeptide of specific binding rare earth nanoparticle and screening method thereof Download PDFInfo
- Publication number
- CN103145798B CN103145798B CN201210260132.9A CN201210260132A CN103145798B CN 103145798 B CN103145798 B CN 103145798B CN 201210260132 A CN201210260132 A CN 201210260132A CN 103145798 B CN103145798 B CN 103145798B
- Authority
- CN
- China
- Prior art keywords
- rare earth
- ucn
- seq
- polypeptide
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 132
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 76
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 59
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 53
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 52
- 150000002910 rare earth metals Chemical class 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title abstract description 18
- 238000012216 screening Methods 0.000 title abstract description 9
- 230000009870 specific binding Effects 0.000 title abstract description 9
- 230000027455 binding Effects 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 39
- 239000002245 particle Substances 0.000 abstract description 14
- 238000004113 cell culture Methods 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000003993 interaction Effects 0.000 abstract description 6
- 239000000725 suspension Substances 0.000 abstract description 6
- 230000002776 aggregation Effects 0.000 abstract description 2
- 238000004220 aggregation Methods 0.000 abstract description 2
- 239000011247 coating layer Substances 0.000 abstract description 2
- 239000002086 nanomaterial Substances 0.000 description 44
- PLDDOISOJJCEMH-UHFFFAOYSA-N neodymium oxide Inorganic materials [O-2].[O-2].[O-2].[Nd+3].[Nd+3] PLDDOISOJJCEMH-UHFFFAOYSA-N 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000006059 cover glass Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- -1 rare earth sulfides Chemical class 0.000 description 8
- 238000004062 sedimentation Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 6
- 239000005642 Oleic acid Substances 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229910052769 Ytterbium Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012984 biological imaging Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 229910001404 rare earth metal oxide Inorganic materials 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- OBOSXEWFRARQPU-UHFFFAOYSA-N 2-n,2-n-dimethylpyridine-2,5-diamine Chemical compound CN(C)C1=CC=C(N)C=N1 OBOSXEWFRARQPU-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- DBTMQODRSDEGRZ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-oxoethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCC=O)C3=CC=CC=C3C2=C1 DBTMQODRSDEGRZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010033708 GFE-1 peptide Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229910020489 SiO3 Inorganic materials 0.000 description 1
- 108010016555 SmacN7 peptide Proteins 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- HDGGAKOVUDZYES-UHFFFAOYSA-K erbium(iii) chloride Chemical compound Cl[Er](Cl)Cl HDGGAKOVUDZYES-UHFFFAOYSA-K 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- CKLHRQNQYIJFFX-UHFFFAOYSA-K ytterbium(III) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Yb+3] CKLHRQNQYIJFFX-UHFFFAOYSA-K 0.000 description 1
- FIXNOXLJNSSSLJ-UHFFFAOYSA-N ytterbium(III) oxide Inorganic materials O=[Yb]O[Yb]=O FIXNOXLJNSSSLJ-UHFFFAOYSA-N 0.000 description 1
- RUDFQVOCFDJEEF-UHFFFAOYSA-N yttrium(III) oxide Inorganic materials [O-2].[O-2].[O-2].[Y+3].[Y+3] RUDFQVOCFDJEEF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a polypeptide of a specific binding of rare earth nanoparticle and a screening method thereof. The polypeptide can be combined on surface of the nanoparticle to form a coating layer, thereby improving suspension ability of rare earth nanoparticles in water, preventing aggregation between particles, reducing interaction between particles, and reducing nonspecific adhesion ability of rare earth nanoparticles with cell surface, cell culture plate surface and other medium surfaces.
Description
Technical Field
The invention belongs to the field of nano biology, and particularly relates to a polypeptide specifically bound with rare earth nanoparticles and a screening method thereof.
Background
The up-conversion luminescent nanoparticles (UCN) based on rare earth are used as a new generation of bioluminescent markers, and compared with down-conversion luminescent markers such as organic fluorescent dyes and quantum dots, the up-conversion luminescent nanoparticles have the advantages of good photostability, high chemical stability, narrow absorption and emission bands, long luminescent life, small potential biotoxicity and the like. The upconversion luminous marker adopts near-infrared continuous laser as an excitation source, has the remarkable advantages of deeper light penetration depth, no biological background fluorescence interference, almost no damage to biological tissues and the like, and becomes an ideal marker for biological imaging. In addition, the rare earth up-conversion nano material is rare earth doped fluoride nano particles, has lower phonon energy, can reduce non-radiative transition and improve luminous intensity, is separated from a plurality of matrixes such as oxides, sulfides, phosphides and the like, and is widely applied to the fields of analysis and detection, disease treatment and the like in recent years.
However, rare earth upconversion nanoparticles as inorganic nanoparticles have presented a number of problems prior to their use in vivo applications and clinical trials. For example, it is easily agglomerated and insoluble in water, and is difficult to apply to the in vivo environment; when the compound is applied to in vivo biological imaging and in vivo photodynamic therapy, the compound can be non-specifically adhered to a plurality of tissues, cells and biomolecules to influence the action effect; enter cells or animals, which can cause severe autophagy and even cell death.
Currently, the surface modification method for inorganic nanoparticles mainly uses silica gel (CN 101434748), fatty acid (CN 1400167), polyethylene glycol (CN 101038290), chitosan (CN 101411893), protein, polypeptide, etc. to improve the surface characteristics of nanoparticles by various covalent and non-covalent means. Among these methods, of note is the surface modification by encapsulation with a coating of a specific binding peptide, which has uneconomical versatility, biocompatibility, simplicity and extendibility. At present, specific binding polypeptides mainly reported at home and abroad are mainly aimed at binding tissues, organs, cells and proteins in vivo and in vitro. For example, polypeptides that specifically bind to normal or cancerous tissue organs (CN 101531706, CN101827583A, CN1563078, CN102060909A, CN 101891803A); polypeptides that specifically bind to normal or cancerous cells (CN 101918433A, CN1709905, CN1763082, CN101033251, CN 1900108); and polypeptides that specifically bind to proteins in vivo (CN 102060913A, CN1823087, CN1262688, CN102105487A, CN101146822, CN1721432, CN1687128, CN101225108, CN101113164, CN 101481418). However, there are few reports of specific binding polypeptides for inorganic nanoparticles, the only ones being binding polypeptides for titanium, silver, silicon materials (CN 1829734) and high affinity binding peptides for metallic nickel (CN 1911956).
Disclosure of Invention
The invention provides a method for screening out polypeptide with the capacity of specifically binding rare earth nanoparticles by using a phage display library by using a phage display technology. The method of the invention comprises the following steps: (a) mixing and incubating a phage display polypeptide library and rare earth nanoparticles; (b) recovering the phage bound to the rare earth nanoparticles; (c) the amplified and recovered phage is used for the next round of combination screening of the rare earth nanoparticles; (d) repeating the steps (a) to (c) at least once; (e) and (4) picking a monoclonal from the recovered phage, and sequencing to obtain the encoded display polypeptide. In the examples, the polypeptide identified using the methods of the invention has a nucleotide sequence encoding display polypeptide CTARSPWIC (RE-0, SEQ ID NO: 1). The phage carrying the displayed polypeptide shows the ability to specifically bind to rare earth nanoparticles with high affinity.
The invention also provides the chemical synthesis of high affinity polypeptide and analogues thereof, which specifically bind to rare earth nanoparticles, and the analogues comprise amino acid sequences identified by phage display technology screening. Specific polypeptides, including amino acid sequences comprising phage-displayed peptides, and analogs thereof, have been shown to be capable of highly specific binding to rare earth nanomaterials. These rare earth nanomaterials include rare earth oxides, rare earth sulfides, rare earth oxysulfides, up-conversion luminescent nanomaterials based on rare earth doping, and all compounds containing rare earth elements. Any production techniques for such polypeptides or proteins known to those skilled in the art, including but not limited to expression of the peptides or proteins by standard molecular biology techniques such as recombinant techniques, isolation of the peptides or proteins from natural sources, or chemical synthesis of such peptides or proteins, are included within the scope of the present invention.
In a preferred embodiment, a polypeptide having sequence ACTARSPWICG (RE-1, SEQ ID NO: 2) was synthesized, where RE-1 includes the sequence of RE-0, the RE-0 sequence plus the two terminal amino acids A and G, derived from the coat protein of bacteriophage M13. In other embodiments, polypeptide analogs of RE-1 are also synthesized. These polypeptide analogs include RE-3 (ACWPATRISCG, SEQ ID NO: 4), which is formed by leaving each of the 2 amino acids at both ends of RE-1 unchanged and disrupting the sequence of the middle seven amino acids; RE-2X (ACTARSPWICGGGACTARSPWICG, SEQ ID NO: 13), which is composed of two RE-1 s. The high affinity ability of these polypeptides and their analogs to specifically bind to rare earth nanomaterials has been demonstrated.
In other embodiments, polypeptide analogs of RE-1 are also synthesized. These polypeptide analogs include RE-2 (TARSPWI, SEQ ID NO: 3), which is composed of the middle seven amino acids remaining after removal of 2 amino acids from both ends of RE-1; RE-4 (AATARSPWICG, SEQ ID NO: 5), which is a single amino acid substitution of RE-1 (C → A); RE-5 (ACAARSPWICG, SEQ ID NO: 6), which is a single amino acid substitution of RE-1 (T → A); RE-6 (ACTAASPWICG, SEQ ID NO: 7), which is a single amino acid substitution of RE-1 (R → A); RE-7 (ACTARAPWICG, SEQ ID NO: 8), which is a single amino acid substitution of RE-1 (S → A); RE-8 (ACTARSAWICG, SEQ ID NO: 9), which is a single amino acid substitution of RE-1 (P → A); RE-9 (ACTARSPAICG, SEQ ID NO: 10), which is a single amino acid substitution of RE-1 (W → A); RE-10 (ACTARSPWACG, SEQ ID NO: 11), which is a single amino acid substitution of RE-1 (I → A); RE-11 (ACTARSPWIAG, SEQ ID NO: 12), which is a single amino acid substitution of RE-1 (C → A). These polypeptides and analogs thereof have demonstrated the ability to bind rare earth nanomaterials with general affinity.
In other embodiments, polypeptide analogs of RE-1 are also synthesized. These polypeptide analogs include RE-Ag (ACTARSPWICGGGNPSSLFRYLPSD, SEQ ID NO: 14), which is composed of RE-1 and metallic silver specific binding peptide (NPSSLFRYLPSD), which has been shown to bind specifically with high affinity to both rare earth nanoparticles and metallic silver. RE-Ti (RKLPDAGGGACTARSPWICG, SEQ ID NO: 15), which is composed of RE-1 and metallic titanium specific binding peptide (RKLPDA), has been demonstrated to bind specifically with high affinity to both rare earth nanoparticles and metallic titanium. RE-AT (CLSYYPSYCGGACTARSPWICG, SEQ ID NO: 16), which is composed of RE-1 and apoptotic cell targeting peptide (CLSYYPSYC), has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to the apoptotic cell surface. RE-PH (SMSIARLGGACTARSPWICG, SEQ ID NO: 17), which is composed of RE-1 and prostate tissue targeting peptide (SMSIARL), has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to prostate tissue. RE-BH (CLEVSRKNCGGACTARSPWICG, SEQ ID NO: 18), which consists of RE-1 and brain tissue targeting peptide (CLEVSRKNC), has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to brain tissue. RE-LH (CGFECVRQCPERCGGACTARSPWICG, SEQ ID NO: 19), which consists of RE-1 and lung tissue targeting peptide (CGFECVRQCPERC), has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to lung tissue. RE-DH (ACTARSPWICGGPKKKRKVC, SEQ ID NO: 20), which is composed of RE-1 and a nucleic acid localization Peptide (PKKKRKV), has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to the nucleus. RE-SMAC (ACTARSPWICGGGAVPIAQK, SEQ ID NO: 21), which is composed of RE-1 and the pro-apoptotic polypeptide SMAC (AVPIAQK), has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to apoptotic cells. RE-1-RGD (CRGDCGGACTARSPWICG, SEQ ID NO: 22), which is composed of RE-1 and tumor cell targeting peptide RGD, has been shown to not only bind specifically with high affinity to rare earth nanoparticles, but also target rare earth nanoparticles to tumor cells.
The invention also provides isolated nucleotides, homologs and analogs that encode, or hybridize under stringent conditions to, a nucleotide sequence encoding, for example, polypeptide RE-0 (SEQ ID NO: 1), RE-1 (SEQ ID NO: 2), RE-2X (SEQ ID NO: 13), RE-3 (SEQ ID NO: 4) or a portion thereof, or a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding SEQ ID NO: 1. SEQ ID NO: 2. SEQ ID NO: 13. SEQ ID NO: 4 or the amino acid sequences shown in the parts of the sequences have the high-affinity ability of specifically binding the rare earth nanoparticles. Further, the invention also provides nucleotides, homologs and analogs including those encoding SEQ ID NO: 1. SEQ ID NO: 2. SEQ ID NO: 13. SEQ ID NO: 4, a portion thereof, or a nucleotide sequence that is the complement thereof.
The invention also provides a method for evaluating the suspension capacity of the nano material, which comprises the following steps: (a) placing the nanometer material suspension in an ultraviolet detection pool; (b) the ultraviolet characteristic absorption wavelength of the nano material is used for carrying out real-time observation and scanning on the nano material in the sample cell to obtain a time dynamics curve; (c) and (4) evaluating the suspension capacity of the nano material according to a time kinetic curve.
The invention also provides a method for evaluating the sedimentation rate and the diffusion capacity of the nano material and the interaction with cells, which comprises the following steps: (a) culturing cells on a cover glass, respectively placing the cells with the front side facing upwards or the cells with the front side facing downwards in a cell culture plate, and placing the cover glass on a small glass body; (b) pouring the nano material culture medium into a cell culture plate, so that the cells are fully immersed in the culture medium, and the position of the cell cover glass is just positioned at the middle height of the liquid; (c) observing the bound nanomaterial on the cell surface with a fluorescence microscope equipped with an infrared laser; (d) and evaluating the sedimentation rate and the diffusion capacity of the nano material and the interaction with cells according to the fluorescence observation result.
The invention also provides a device for evaluating the sedimentation rate and the diffusion capacity of the nano material and the interaction with cells, which comprises a cell culture plate, a cover glass and a small glass body, wherein the small glass body is positioned in the cell culture plate, and the cover glass is erected on the small glass body.
The invention provides a polypeptide capable of specifically binding rare earth nanoparticles with high affinity, which can be bound on the surfaces of the nanoparticles to form a coating layer, so that the suspension performance of the rare earth nanoparticles in water is improved, the aggregation among the particles is prevented, the interaction among the particles is reduced, and the nonspecific adhesion capacity of the rare earth nanoparticles to the surfaces of cells, the surfaces of cell culture plates and other media is also reduced.
Drawings
FIG. 1 shows the specificity with Nd2O3Number of phage bound results.
FIG. 2 is a graph showing the confirmation of REOB-1 phage and Nd2O3PCR results plot of binding capacity.
FIG. 3 shows the different concentrations of RE-1 short peptide vs. REOB-1 phage and Nd2O3Results of inhibition of binding ability.
FIG. 4 is a graph showing the binding ability of RE-1 short peptide with different inorganic nano-materials.
FIG. 5 is a graph showing the results of the characterization of UCN binding to RE-1. Wherein, FIG. 5A is a transmission electron micrograph of the combination of UCN and RE-1 short peptide; FIG. 5B is a transmission electron micrograph of UCN bound to REOB-1 phage; FIG. 5C is a scanning electron micrograph of the binding of UCN to RE-1 short peptide.
Fig. 6 is a graph showing the results of particle size analysis of the upconversion luminescent nanomaterials. Wherein, fig. 6A is a particle size distribution of UCN; FIG. 6B is a particle size distribution of UCP; FIG. 6C shows the particle size distribution of UCN-S.
FIG. 7 is a graph of the binding of the upconversion luminescent nanomaterials to RE-1. Wherein FIG. 7A (UCN) and FIG. 7B (UCP) are combined time gradient curves; FIG. 7C (UCN), FIG. 7D (UCP) and FIG. 7E (UCN-S) are combined concentration gradient curves.
FIG. 8 is a graph of the effect of the environment on the binding of the upconversion luminescent nanomaterial to RE-1. Wherein FIG. 8A (UCN) and FIG. 8B (UCP) are the effect of different pH values; FIG. 8C (UCN) and FIG. 8D (UCP) are the effect of different salt ion concentrations; FIG. 8E (UCN) and FIG. 8F (UCP) are the effects of different temperatures.
FIG. 9 shows the dissociation of RE-1 bound to the upconversion luminescent nanomaterial over time. Wherein, fig. 9A shows the dissociation result of UCN; fig. 9B shows the dissociation result of UCP.
FIG. 10 is a graph showing the results of time-kinetic curves of RE-1 improving the suspension ability of the upconversion luminescent nanomaterial. Wherein, fig. 10A is a time kinetic curve of UCN; fig. 10B is a time kinetic curve of UCP.
FIG. 11 is a graph showing the results of the detection of nonspecific adhesion ability of RE-1 to reduce the upconversion luminescent nanomaterial. Wherein, fig. 11A and 11B are detection results of UCNs; FIGS. 11C and 11D show the results of UCN-S detection.
FIG. 12 is a graph showing the results of the detection of RE-1 reducing the diffusion ability of the upconversion luminescent nanomaterial in a solution. Wherein, fig. 12A and 12B are schematic diagrams of the experimental apparatus; fig. 12C, 12D, and 12E show the detection results of UCNs; fig. 12F, 12G, and 12H show the detection results of UCP.
Detailed Description
The present invention will be further described with reference to the following specific examples. It should be understood that the following examples are illustrative only and are not intended to limit the scope of the present invention.
Examples1. Screening specificity and Nd by phage display technology2O3Conjugated short peptides
For screening specificity and Nd2O3The library of bound peptides, provided by New England Biolabs (Mass, MA), is a library of heptapeptides containing disulfide bonds (Ph.D. -C7C). The random fragments in this library are flanked by cysteine residues that can be oxidized during phage assembly to form disulfide bonds, thus forming a cyclic peptide that interacts with the target. This library contained over two billion clones. The random peptide in the library was at the amino terminus of the small coat protein pIII, so five copies were expressed per phage particle. The position of the phage expression random sequence in the ph.d. -C7C library was preceded by alanine-cysteine. A short linker sequence (glycine-serine) is contained between the random peptide and the pIII protein. (Ph.D.TM-C7C phage peptide display kit, http:// www.neb.com/nebecom/products E8120. asp). 2. mu.l of 1010Phage and 1ml Nd2O3(1 mg/ml, available from Whitzel chemical, Guangzhou.) and incubated at 37 ℃ for 2h in a shaker, after centrifugation at 12000rpm for 10min, the pellet was washed 10 times with TBST (containing 2% Tween-20, pH 7.5) to bind Nd2O3The phage were recovered and then mixed with 0.5ml of E.coli ER2378 (purchased from New England Biolabs, Mass., MA), incubated for 0.5h and amplified for 6h in 20ml of LB medium (tryptone 0.2 g; yeast extract 0.1 g; sodium chloride 0.2 g). The amplified phage were resuspended in phosphate buffer (150 mM NaCl, 50mM Tris-HCl, pH 7.5) and used for a second round of selection. Approximately 100 phages were recovered in the first round, and the third round of amplified phages were mixed with Nd2O3The binding efficiency of (A) was improved by two orders of magnitude over the phage library (FIG. 1).
The third round of recovered phage was plated on LB plates containing X-gal (5-bromo-4-chloro-3-indolyl-. beta. -D-galactolactose) and IPTG (isoproyl-. beta. -D-thiogalactoside), and 15 blue plaques were randomly picked and sequenced using an automatic DNA sequencer (ABI 3730). 12 of these (designated REOB-1) contained identical inserts, and the encoded peptide sequence was CTARSPWIC (RE-0, SEQ ID NO: 1).
Example 2Identification of REOB-1 phage and Nd2O3Bonding force of (2)
The titer was 105The REOB-1 phage and the titer of 108AP-1 phage (random phage randomly selected from phage library, used as a control, encoding a peptide sequence of CNATLPHQC, SEQ ID NO: 23) of (1) was mixed with 100. mu.l of Nd2O3(1 mg/ml) was incubated at 37 ℃ for 2h, centrifuged at 12000rpm for 10min, the pellet was washed 10 times with TBST (containing 2% Tween-20, pH 7.5), and phage bound in the pellet were eluted with 1ml of 0.2M glycine-hydrochloric acid (pH 2.2) containing 1mg/ml BSA and plated on LB plates. Randomly pick 50 blue plaques, and each plaque is subjected to a double PCR reaction simultaneously. One was performed with a primer specific to REOB-1 phage (5'-CGAGGTCGCCTTGGATTTGC-3') and one was performed with a primer specific to AP-1 phage (5'-GACCAGTCGCATCCGCAGCA-3'). The additional primers required for the PCR reaction consist of sequences on the vector, shared for both reactions. The PCR product was subjected to 0.8% agarose gel electrophoresis, and the result was photographed by a gel imaging system (Tanon 1600, Tanon, China). The results show that, since the titers of the added REOB-1 phage and AP-1 phage differ by a factor of 1000, the results of PCR REOB-1: AP-1= 12: 1, thus REOB-1 phage and Nd2O3The binding force was 12000 times higher than for the AP-1 phage.
Examples3. Chemical synthesis of specific binding peptides and analogs thereof
The polypeptides in this application were synthesized by Shanghai Jier Biochemical company using standard FMOC solid phase synthesis in an automated polypeptide synthesizer (CS 536-1381, CS Bio Co., Menlo Park, Calif.) and purified to greater than 95% purity by HPLC and molecular weights were determined using a mass spectrometer (ThermoFisher Scientific, Thermo, USA).
The peptide of sequence ACTARSPWICG (RE-1, SEQ ID NO: 2) was synthesized as follows. The terminal amino acids alanine and glycine were derived from the M13 surface protein. RE-1 was synthesized using standard FMOC solid phase synthesis, generally by the manual synthesis procedure as follows: approximately 0.2mM Fmoc-Gly-Wang resin was added to a manual reaction tube (Peptide International) and DMF was added to swell it for 2 h. The Fmoc protecting group was then removed by addition of 20% piperidine/DMF for 2min and the deprotection step was repeated once and ice reacted for 20 min. A positive Kaiser test indicated free amino groups on the resin. Amino acid residues were added to the resin according to the following cycle method: a three-fold excess of Fmoc protected amino acids, a three-fold excess of HOBT and a three-fold excess of DIPEA/DMF were added to the reaction tube according to the sequence of RE-1. In N2The coupling reaction was carried out for 2h in stream and the reaction tubes were evacuated with a vacuum pump. The N-terminally protected peptide was washed with DMF (5X 1 min) to remove excess reactants, and then the Fmoc protecting group was removed with 20% piperidine/DMF as before. The reaction tube was washed with DMF to remove the piperidine and repeated steps were performed to couple the next amino acid in the sequence. Synthesis of N with side chain protectionaAfter Fmoc-Ala-Cys-Thr-Ala-Arg-Ser-Pro-Trp-Ile-Cys-Gly-resin conjugate, the peptide resin conjugate was washed with DMF (4X 1 min) and dried in vacuo. The amino-terminal Fmoc protecting group was removed with 20% piperidine/DMF. Deprotection of the side chains and cleavage of the peptide resin bond were reacted with 10ml of lysis buffer (95% trifluoroacetic acid, 2.5% water and 2.5% triisopropylsilane) for 3h with shaking at 500 rpm. The reaction was transferred to a pre-weighed Erlenmeyer flask and precipitated with ice dry ether. The crude product was dried in vacuo for 48 h. 70-100mg of the crude product was purified by reverse phase high performance liquid chromatography (RP-HPLC) and lyophilized to a powder. The purity of the peptide was determined by analytical RP-HPLC and its molecular weight was determined by mass spectrometry.
Control peptide ACNATLPHQCG (AP-1, SEQ ID NO: 24) and polypeptide analogs and derivatives were synthesized using the same method described above. AP-1 is an 11 peptide with identical terminal amino acids and contains irrelevant internal sequences. FITC was coupled to the amino terminus of RE-1 and AP-1 via Acp.
Examples4. Identification of polypeptide analogs and Nd2O3Bonding force of (2)
100. mu.g of Nd2O3Mixing with polypeptide such as RE-1, AP-1, RE-2, RE-3, RE-4, RE-5, RE-6, RE-7, RE-8, RE-9, RE-10, etc., respectively, and adding the mixture to a mixer with titer of 108The REOB-1 phage was incubated for 2 hours, and Nd was detected2O3Amount of bound REOB-1 phage. IC (integrated circuit)50The values reflect the relative activity of various polypeptides to compete for inhibition of REOB-1 phage binding to neodymia nanometers. The results are shown in Table 1, with polypeptide RE-1 and its analogs and Nd2O3With varying degrees of binding.
TABLE 1 Polypeptides RE-1 and analogs thereof with Nd2O3Bonding force of (2)
Examples5. RE-1 short peptide inhibits REOB-1 and Nd2O3In combination with
Mixing RE-1 short peptide (0. mu.g/ml, 1. mu.g/ml, 10. mu.g/ml, 50. mu.g/ml, 100. mu.g/ml, 500. mu.g/ml) with different concentration gradient and the content of the mixture with the titer of 108100. mu.l Nd of REOB-1 phage2O3(1 mg/ml) was incubated at 37 ℃ for 2h, the pellet was washed 10 times, and bound Nd was recovered2O3The bacteriophage of (1). Meanwhile, 5000. mu.g/ml of AP-1 short peptide was used as a control in the same manner. The results show that when RE-1 and REOB-1 are combined with Nd2O3In combination, RE-1 couples REOB-1 with Nd as the dose increases2O3Has inhibitory effect on binding ability of (A). When it exceeds 10. mu.g/ml, RE-1 almost completely inhibits REOB-1 and Nd2O3Binding capacity (FIG. 3). The RE-1 short peptide is proved to have competitive inhibition effect on REOB-1 phage, REOB-1 and Nd2O3Due to the specific interaction of the peptide it displays with the nanomaterial surface.
Examples6. Testing the binding capacity of RE-1 short peptide and various nano materials
Mu.g of FITC-RE-1 polypeptide is respectively incubated with 100 mu.l of a plurality of different inorganic nano-materials (1 mg/ml) for 1h at room temperature, then the mixture is centrifuged at 12000rpm for 10min, and after 3 times of precipitate washing, FITC (emission wavelength is 535 nm) is detected by a fluorescence spectrophotometer (RF-5301 PC, Shimadzu, Japan), and a standard curve of the relationship between FITC-RE-1 fluorescence and concentration is used as a control to obtain the binding capacity of the different materials and the FITC-RE-1 polypeptide. The results show that RE-1 has stronger binding capacity with rare earth metal oxide and rare earth element doped up-conversion luminescent nano-material, wherein Y2O3,CeO2,Yb2O3,Nd2O3The binding ability of UCN (upconversion luminescent nanomaterials), UCN-S (small particles of UCN) and UCP (large particles of UCN) is strongest. And RE-1 with non-rare earth materials, e.g. diamond, TiO2,SiO2,SiO3And nanosilver were almost unbound (fig. 4).
Examples7. Method for synthesizing UCN (NaYF 4: Yb, Er)
Spherical NaYF 4: the 18% Yb, 2% Er nanoparticles were synthesized as follows. Yttrium chloride (0.1562 g), ytterbium chloride (0.0503 g), erbium chloride (0.0055 g) were mixed with 3ml of oleic acid and 17ml of octadecene in a 50ml flask, heated to 160 ℃, and then cooled to room temperature. Sodium hydroxide (0.01 g) and ammonium fluoride (0.148 g) were dissolved in 10ml of methanol and added dropwise to the flask, and stirred for 30min to ensure sufficient reaction of the chloride. The solution was slowly heated to evaporate the methanol, degassed at 100 ℃ for 10min, then heated to 300 ℃ under argon and maintained for 1 h. The solution is naturally cooled and the nano-crystals are precipitated. After precipitation with ethanol and three washes with ethanol/water (1: 1 by volume), the surface was treated with 1M hydrochloric acid for 5h at room temperature to remove oleic acid and washed 10 times with water and cyclohexane. The characteristic absorption peak of oleic acid at 230nm was detected to ensure its complete removal. UCN and UCN-S were synthesized by adding varying amounts of oleic acid (UCN: 3ml oleic acid, UCN-S: 6ml oleic acid). The synthesized UCN was stored in water for use.
Examples8. Observation of binding form of RE-1 short peptide to UCN
The binding pattern of RE-1 short peptide and REOB-1 phage to UCN was observed using a transmission electron microscope. The complex of RE-1 and UCN bound together was washed away with excess, unbound polypeptides and phage, and the bound product was stained with uranium acetate (ph 6.7) and placed on a carbon film-coated copper mesh. The images were observed using a transmission electron microscope TEM (JEM-2100F, JEOL, Japan) at 200 kv (fig. 5A and 5B).
The binding form of RE-1 short peptide to UCN was observed by scanning electron microscope. The complex of RE-1 and UCN bound together was washed away for excess unbound polypeptide, the bound product was placed on a copper plate, and the image was observed using a 15 kV scanning electron microscope SEM (JEOL JSM-6700F, JEOL, Japan) (FIG. 5C).
The results show that REOB-1 phage can be tightly bound to UCN surface with high affinity, and RE-1 short peptide can form stable peptide layer on UCN surface.
Examples9. Identification of up-conversion luminescent nano material (UCN, UCP, UCN-S) in nano scale
The synthesized UCN and UCN-S and UCP (Phosphor Technology, UK) subjected to ultrasonic disintegration sedimentation were dissolved in water, the solution was placed in a square polystyrene cell (DTS 0012, Malvern, UK), and the particle size distribution of the nanoparticles was measured using a Malvern Nano laser particle sizer (Nano ZS90, Malvern, UK) with a 633nm helium/neon laser. The results show that the size scale for UCN is about 92nm (fig. 6A), for UCP is about 500nm (fig. 6B), and for UCN-S is about 20nm (fig. 6C).
Examples10. Testing the binding capacity of RE-1 short peptide and up-conversion luminescent nano material (UCN, UCP, UCN-S)
Mu.g of FITC-RE-1 was incubated with 100. mu.g of UCN for various periods of time (2 min, 10min, 30min, 120min, 720 min), and the amount of FITC-RE-1 fluorescent peptide bound to UCN was then detected using a spectrofluorometer. The results show that RE-1 binds to UCN very rapidly, 50% already at 2min, and almost saturation of binding is achieved at 10min (FIG. 7A).
Mu.g of FITC-RE-1 was incubated with 100. mu.g of UCP for various periods of time (2 min, 10min, 30min, 120min, 720 min), and the amount of FITC-RE-1 fluorescent peptide bound to UCP was then detected using a spectrofluorometer. The results show that the binding of RE-1 to UCP also has a time-kinetic distribution, and at 2min, 50% is already bound, and 10min almost reaches the binding saturation (FIG. 7B).
After incubating 100. mu.g of UCN with different concentrations (5. mu.g, 10. mu.g, 25. mu.g, 50. mu.g, 100. mu.g) of FITC-RE-1 for 1h, excess unbound peptides were washed off, and the amount of FITC-RE-1 fluorescent peptide bound to UCN was then detected using a spectrofluorometer. The results showed that 100. mu.g of UCN was able to bind 47. mu.g of FITC-RE-1 (FIG. 7C).
After incubating 100. mu.g of UCP with different concentrations (1. mu.g, 5. mu.g, 10. mu.g, 20. mu.g) of FITC-RE-1 for 1h, excess unbound peptides were washed off, and the amount of FITC-RE-1 fluorescent peptide bound to UCP was then detected using a spectrofluorometer. The results showed that 20. mu.g of UCP was able to bind 9.2. mu.g of FITC-RE-1 (FIG. 7D).
After incubating 100. mu.g of UCN-S with different concentrations (50. mu.g, 100. mu.g, 200. mu.g, 300. mu.g, 400. mu.g) of FITC-RE-1 for 1h, excess unbound peptides were washed away, and the amount of FITC-RE-1 fluorescent peptide bound to UCN-S was then detected using a spectrofluorometer. The results showed that 400. mu.g of UCN-S was able to bind 301. mu.g of FITC-RE-1 (FIG. 7E).
Examples11. Influence of solution environment on binding capacity of RE-1 short peptide and up-conversion luminescent nano material (UCN, UCP)
After incubating 50. mu.g of FITC-RE-1 with 100. mu.g of UCN dissolved at different pH values (3, 5, 7, 10) for 1h, the excess unbound peptides were washed off and the amount of FITC-RE-1 fluorescent peptide bound to UCN was measured by a spectrofluorometer. The results show that the binding of FITC-RE-1 to UCN is not sensitive to pH changes in the solution environment (FIG. 8A).
After incubating 10. mu.g of FITC-RE-1 with 100. mu.g of UCP dissolved at different pH values (3, 5, 7, 10) for 1h, the excess unbound peptides were washed off and the amount of FITC-RE-1 fluorescent peptide bound to UCP was measured using a spectrofluorometer. The results show that the binding of FITC-RE-1 to UCP is not sensitive to pH changes in the solution environment (FIG. 8B).
After incubating 50. mu.g of FITC-RE-1 with 100. mu.g of UCN dissolved in solutions of different salt ion concentrations (0M, 0.15M, 0.3M, 0.5M sodium chloride) for 1h, excess unbound peptides were washed off, and the amount of FITC-RE-1 fluorescent peptide bound to UCN was then detected using a spectrofluorometer. The results show that the binding of FITC-RE-1 to UCN is not sensitive to changes in the salt ion concentration in the solution environment (FIG. 8C).
After incubating 10. mu.g of FITC-RE-1 with 100. mu.g of UCP dissolved in solutions of different salt ion concentrations (0M, 0.15M, 0.3M, 0.5M sodium chloride) for 1h, excess unbound peptides were washed off, and the amount of FITC-RE-1 fluorescent peptide bound to UCP was then detected using a spectrofluorometer. The results show that binding of FITC-RE-1 to UCP is not sensitive to changes in the salt ion concentration in the solution environment (FIG. 8D).
50 mu g of FITC-RE-1 and 100 mu g of UCN dissolved in water are incubated for 1h in environments with different temperatures (25 ℃, 37 ℃, 55 ℃ and 80 ℃), redundant unbound peptides are washed away, and then the amount of FITC-RE-1 fluorescent peptide bound to UCN is detected by a fluorescence spectrophotometer. The results showed that binding of FITC-RE-1 to UCN was not sensitive to changes in ambient temperature (FIG. 8E).
After incubating 10. mu.g of FITC-RE-1 and 100. mu.g of UCP dissolved in water in different temperature environments (25 ℃, 37 ℃, 55 ℃ and 80 ℃) for 1h, washing off the surplus unbound peptides, and then detecting the amount of FITC-RE-1 fluorescent peptide bound to UCP by using a fluorescence spectrophotometer. The results showed that binding of FITC-RE-1 to UCP was not sensitive to changes in ambient temperature (FIG. 8F).
In summary, RE-1 and the up-conversion luminescent nano-materials (UCN, UCP) have extremely strong binding capacity, and the change of the surrounding environment can not destroy the binding force between the peptide and the nano-materials.
Examples12. Testing the dissociation condition of RE-1 short peptide and up-conversion luminescent nano material (UCN, UCP)
Mu.g of FITC-RE-1 was well bound to 500. mu.g of UCN, excess unbound polypeptides were washed off, the mixture was then divided evenly into five equal portions, gently shaken on a shaker at 37 ℃ and the amount of dissociated FITC-RE-1 in the supernatant was measured with a spectrofluorometer at different time points (0 h, 2h, 12h, 24h, 48 h), respectively. The results showed that RE-1 was stably associated with UCN, and only dissociated after 48h to less than 0.7% (FIG. 9A).
The amount of FITC-RE-1 dissociated in the supernatant was determined by mixing 50. mu.g of FITC-RE-1 with 500. mu.g of UCP according to the above procedure. The results showed that RE-1 was also stably associated with UCP, and only dissociated after 48h to less than 1.5% (FIG. 9B).
Examples13. RE-1 reduces the sedimentation velocity of the up-conversion luminescent nano material (UCN, UCP)
3mg of UCN was combined with 1.5mg of RE-1 and its analogues RE-2, RE-3, RE-5 and PEG, respectively, according to the binding method, excess unbound RE-1 was washed off, the precipitate was resuspended in 3ml of water, and after 1min of sonication, placed in an ultraviolet detection cell (X72053, Alpha Laboratories Ltd, UK), and then continuously observed for 120min at an absorption wavelength of 500nm with an ultraviolet spectrophotometer (DU-640, Beckman, USA), to obtain a time kinetic curve. The results showed that UCN without encapsulated RE-1 short peptide precipitated to the bottom of the pool very quickly, while UCN encapsulated RE-1 short peptide remained suspended after resting for 120min, indicating that RE-1 could effectively reduce the sedimentation rate of UCN (FIG. 10A).
A time kinetic curve was obtained by operating 3mg of UCP with 500. mu.g of RE-1 and its analogues RE-2, RE-3, RE-4, RE-5, RE-6, RE-7, RE-8, RE-9, RE-10 and AP-1, respectively, according to the above procedure. The results showed that UCP without encapsulated RE-1 short peptide precipitated to the bottom of the pool very quickly, while UCP encapsulated RE-1 short peptide remained suspended after resting for 120min, indicating that RE-1 could effectively reduce the sedimentation rate of UCP (FIG. 10B).
Examples14. RE-1 reduces the nonspecific adhesion capability of the up-conversion luminescent nano-material (UCN, UCN-S)
Live Hela cells (from shanghai biochemical institute of China academy of sciences), fixed cells and cell culture plates cultured in 96 wells were treated with unencapsulated and RE-1-encapsulated UCN and UCN-S, respectively, and after 2h of treatment, washed 3 times with PBS, and then observed for UCN nanoparticles bound to live Hela cells, fixed cells and cell culture plates with a fluorescence microscope (Olympus IX71, Olympus, Japan) equipped with a 980nm infrared laser (MDL-980 nm 1W, Changchun New Industries Optoelectronics tech. The results showed that non-specific adhesion of RE-1-coated UCN group to Hela live cells, fixed cells and cell culture plates was reduced by about 10-fold compared to non-RE-1-coated UCN group (fig. 11A and 11B); non-specific adhesion of RE-1-coated UCN-S groups to Hela live cells, fixed cells, and cell culture plates was reduced by about 100-fold compared to RE-1-uncoated UCN-S groups (FIGS. 11C and 11D).
Examples15. RE-1 reduces the diffusion capability of up-conversion luminescent nano-materials (UCN, UCP) in solution
Hela cells are cultured on a cover glass (length and width are 22 mm), the cells at the front side are respectively placed in a 6-well plate, the cover glass is put on a sterilized small glass body (length and width are 2 mm), then 4ml of DMEM culture medium (Gibco, USA) containing the up-conversion luminescent nano materials (UCN, UCP) which are not wrapped and wrapped with RE-1 is slowly poured into a six-well plate, so that the cells are fully immersed in the culture medium, and the position of the cell cover glass is just positioned at the middle height of the liquid. And placed in a cell culture chamber at 37 ℃ for 2h, followed by washing 3 times with PBS, and observing the UCNs bound on the cell surface with a fluorescence microscope (Olympus IX71, Olympus, Japan) equipped with a 980nm infrared laser (MDL-980 nm 1W, Changchun New Industries optics Tech.Co., Ltd., China). The results show that for the experimental group with the cell front facing upwards, the upconversion luminescent nanomaterial group without coating RE-1 has a large amount of non-specific adhesion particles, while the upconversion luminescent nanomaterial group coating RE-1 has a great reduction in the amount of cell surface adhesion upconversion luminescent nanoparticles; for the experiment group with cells facing downwards, the non-specific adhesion particles of the upconversion luminescent nanomaterial group without coating RE-1 are reduced slightly compared with the group with cells facing upwards, but the upconversion luminescent nanoparticles adhered on the surface of the cells are much more than those of the upconversion luminescent nanomaterial group coating RE-1. It is demonstrated that RE-1 not only reduces the sedimentation rate of UCNs and UCPs but also reduces the diffusion ability of the upconversion luminescent nanomaterials, whereby RE-1 achieves a reduction of the nonspecific adhesion ability of the upconversion luminescent nanomaterials (fig. 12A and 12B are schematic diagrams of experimental devices, fig. 12C, 12D and 12E are results of UCNs, and fig. 12F, 12G and 12H are results of UCPs).
Claims (2)
1. A polypeptide that specifically binds to a rare earth nanoparticle, wherein the polypeptide is:
(a) as shown in SEQ ID NO: 1;
(b) polypeptide sequences derived from (a) which are subjected to addition, deletion, order change or substitution of one or more amino acids in the polypeptide sequences defined in (a) and are capable of specifically binding to rare earth nanoparticles;
wherein,
the polypeptide sequence which is added with one or more amino acids in the polypeptide sequence defined by (a) and is derived from (a) and can be specifically combined with the rare earth nanoparticles is shown as SEQ ID NO: 2; the polypeptide sequence which is obtained by deleting one or more amino acids in the polypeptide sequence defined by the step (a) and can be specifically combined with the rare earth nanoparticles and is derived from the step (a) is SEQ ID NO: 3; the polypeptide sequence which is subjected to sequence conversion in the polypeptide sequence defined by the step (a) and is derived from the step (a) and can be specifically combined with the rare earth nanoparticles is SEQ ID NO: 4;
the polypeptide sequence which is substituted by one or more amino acids in the polypeptide sequence defined by the (a) and can be specifically combined with the rare earth nanoparticles and is derived from the (a) is SEQ ID NO: 5. SEQ ID NO: 6. SEQ ID NO: 7. SEQ ID NO: 8. SEQ ID NO: 9. SEQ ID NO: 10. SEQ ID NO: 11. SEQ ID NO: 12.
2. A nucleotide sequence comprising a nucleotide sequence encoding the polypeptide sequence of claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210260132.9A CN103145798B (en) | 2012-06-07 | 2012-07-25 | Polypeptide of specific binding rare earth nanoparticle and screening method thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210185635.4 | 2012-06-07 | ||
CN201210185635 | 2012-06-07 | ||
CN201210260132.9A CN103145798B (en) | 2012-06-07 | 2012-07-25 | Polypeptide of specific binding rare earth nanoparticle and screening method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103145798A CN103145798A (en) | 2013-06-12 |
CN103145798B true CN103145798B (en) | 2014-09-10 |
Family
ID=48544163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210260132.9A Expired - Fee Related CN103145798B (en) | 2012-06-07 | 2012-07-25 | Polypeptide of specific binding rare earth nanoparticle and screening method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103145798B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104384494B (en) * | 2014-10-22 | 2016-11-23 | 中国科学技术大学 | RE-1 coating rare earth nanometer particle reduces the inflammatory effector of its induction |
CN104826137B (en) * | 2015-04-30 | 2017-10-10 | 苏州大学 | Method and its vivo applications of the histidine polypeptide to upper conversion nano particle phase transfer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048694A (en) * | 2009-11-06 | 2011-05-11 | 复旦大学 | Polypeptide-modified liver tumor-targeted nano medicine delivery system and preparation method thereof |
CN102060909A (en) * | 2009-11-11 | 2011-05-18 | 中国医学科学院放射医学研究所 | Tumor specific target polypeptide and application thereof |
-
2012
- 2012-07-25 CN CN201210260132.9A patent/CN103145798B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048694A (en) * | 2009-11-06 | 2011-05-11 | 复旦大学 | Polypeptide-modified liver tumor-targeted nano medicine delivery system and preparation method thereof |
CN102060909A (en) * | 2009-11-11 | 2011-05-18 | 中国医学科学院放射医学研究所 | Tumor specific target polypeptide and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103145798A (en) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Uchida et al. | Biological containers: protein cages as multifunctional nanoplatforms | |
Schieber et al. | Conjugation of Transferrin to Azide‐Modified CdSe/ZnS Core–Shell Quantum Dots using Cyclooctyne Click Chemistry | |
US7556863B2 (en) | Gold-coated nanoparticles for use in biotechnology applications | |
EP2928906B1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
US20100040862A1 (en) | Three-Dimensional Structure of Functional Material | |
JP4885542B2 (en) | Peptides capable of binding to titanium, silver and silicon | |
EP2951196A1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
Geng et al. | A general approach to prepare conjugated polymer dot embedded silica nanoparticles with a SiO 2@ CP@ SiO 2 structure for targeted HER2-positive cellular imaging | |
Fujita et al. | Self-assembled artificial viral capsids bearing coiled-coils at the surface | |
Zorko et al. | Studies of cell-penetrating peptides by biophysical methods | |
Wang et al. | Protease-promoted drug delivery using peptide-functionalized gold nanoparticles | |
CN103145798B (en) | Polypeptide of specific binding rare earth nanoparticle and screening method thereof | |
JP5677453B2 (en) | BPB based cargo transport system | |
JP7216031B2 (en) | Metal nanocluster scaffold | |
Phuong et al. | Synthesis and characterization of NaYF4: Yb3+, Er3+@ silica-N= folic acid nanocomplex for bioimaginable detecting MCF-7 breast cancer cells | |
WO2013181947A1 (en) | Polypeptide specifically bonding rare earth nanoparticles and use thereof | |
US10927221B2 (en) | Dendrimeric metallacrowns | |
JP6213453B2 (en) | Separation of rare earth ions | |
KR101352640B1 (en) | Simultaneous Synthesis of Temperature-Tunable Peptide and Gold Nanoparticle Hybrid Spheres | |
JP2012507573A (en) | Neurotensin-derived branched peptides and uses thereof | |
Lim et al. | A cyclic RGD-coated peptide nanoribbon as a selective intracellular nanocarrier | |
ES2565344T3 (en) | Semi-antibodies with self-assembly | |
CN113429461B (en) | Aggregation-induced emission polypeptide micelle type diagnostic reagent and application thereof in near-infrared region biological imaging | |
Niide et al. | Organic crystal-binding peptides: morphology control and one-pot formation of protein-displaying organic crystals | |
Yao et al. | An engineered coiled-coil polypeptide assembled onto quantum dots for targeted cell imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140910 Termination date: 20210725 |